HKEX’s on-demand experts

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise. Its solution is a star-studded advisory panel to identify problems that could sink the sector before it gets off the ground.

On May 4, Hong Kong Exchanges and Clearing Ltd. (HKEX) announced the formation of a biotech advisory panel composed of 13 KOLs from China’s academic, corporate, investment and regulatory communities...